331 related articles for article (PubMed ID: 16569513)
1. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
2. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
3. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells.
Fu X; Tao L; Zhang X
Gene Ther; 2007 Aug; 14(16):1218-25. PubMed ID: 17538637
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
Fu X; Nakamori M; Tao L; Amato R; Zhang X
Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
[TBL] [Abstract][Full Text] [Related]
6. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
Li H; Dutuor A; Tao L; Fu X; Zhang X
Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
[TBL] [Abstract][Full Text] [Related]
7. The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation.
Smith CC; Luo JH; Hunter JC; Ordonez JV; Aurelian L
Virology; 1994 May; 200(2):598-612. PubMed ID: 8178446
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
9. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
10. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth.
Smith CC; Nelson J; Aurelian L; Gober M; Goswami BB
J Virol; 2000 Nov; 74(22):10417-29. PubMed ID: 11044086
[TBL] [Abstract][Full Text] [Related]
11. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.
Perkins D; Pereira EF; Gober M; Yarowsky PJ; Aurelian L
J Virol; 2002 Feb; 76(3):1435-49. PubMed ID: 11773417
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.
Fu X; Tao L; Li M; Fisher WE; Zhang X
Clin Cancer Res; 2006 May; 12(10):3152-7. PubMed ID: 16707615
[TBL] [Abstract][Full Text] [Related]
13. The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity.
Smith CC; Aurelian L
Virology; 1997 Aug; 234(2):235-42. PubMed ID: 9268154
[TBL] [Abstract][Full Text] [Related]
14. Growth-compromised HSV-2 vector Delta RR protects from N-methyl-D-aspartate-induced neuronal degeneration through redundant activation of the MEK/ERK and PI3-K/Akt survival pathways, either one of which overrides apoptotic cascades.
Laing JM; Golembewski EK; Wales SQ; Liu J; Jafri MS; Yarowsky PJ; Aurelian L
J Neurosci Res; 2008 Feb; 86(2):378-91. PubMed ID: 17893911
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
16. The protein kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) fused to the extracellular domain of the epidermal growth factor receptor is ligand-inducible.
Smith CC; Luo JH; Aurelian L
Virology; 1996 Mar; 217(2):425-34. PubMed ID: 8610433
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
18. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.
Peng T; Hunter JR; Nelson JW
Virology; 1996 Feb; 216(1):184-96. PubMed ID: 8614985
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
20. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]